ESPDx is developing scalable liquid-biopsy tests that utilize disease-specific biomarkers from Extracellular Vesicles in blood and saliva to enable early and accurate diagnosis of Lewy Body Dementia and Parkinson’s Disease. This technology addresses the limitations of current diagnostic methods, which are often invasive and costly, by providing a minimally invasive alternative that enhances patient management and supports clinical trial patient stratification.
Funding
Funding not disclosed
Founders
Product
Problem
Current diagnostic methods for Lewy Body Dementia (LBD) and Parkinson’s Disease (PD) rely on lengthy clinical assessments and invasive, costly procedures like PET scans and cerebrospinal fluid (CSF) testing, often after irreversible neuronal loss has occurred. Differentiating between neurodegenerative disorders is challenging due to overlapping symptoms, hindering early intervention and effective patient management.
Solution
ESPDx is developing minimally invasive liquid biopsy tests for early and accurate diagnosis of LBD and PD, utilizing disease-specific biomarkers found in Extracellular Vesicles (EVs) from blood and saliva. This technology offers superior sensitivity and specificity compared to existing methods, enabling detection of neurological disorders in their early stages and facilitating differential diagnosis of Alzheimer's. The tests support patient stratification for clinical trials, monitor disease progression, and accelerate the development of disease-modifying therapies. By providing a scalable and accurate diagnostic tool, ESPDx aims to improve patient outcomes through early intervention and correct medication.
Target Audience
The primary target audience includes clinicians seeking early diagnostic tools for neurodegenerative disorders, pharmaceutical and biotechnology companies developing disease-modifying therapies, and patients at risk of or experiencing symptoms of LBD and PD.
Features
- Scalable liquid biopsy tests using Extracellular Vesicles (EVs) from blood and saliva samples.
- Identification and measurement of disease-specific protein and lipid biomarkers in EVs.
- High sensitivity and specificity for early detection of Lewy Body Disorders (LBD) and Parkinson’s Disease (PD).
- Minimally invasive alternative to PET scanning and cerebrospinal fluid (CSF) testing.
- Potential for patient stratification in clinical trials for neurodegenerative disease therapies.
- Monitoring of disease progression through biomarker analysis.
- Differential diagnosis capabilities to distinguish LBD from Alzheimer's and other neurodegenerative disorders.